In 2018, the market size of Chinese medicine tablets will exceed 270 billion yuan

Driven by the policy, Chinese medicine tablets have become the new favorite of pharmaceutical companies. According to the latest data, the market size of Chinese medicine tablets will exceed 270 billion yuan in 2018. Beijing Business Daily reporter recently visited found that a number of retail pharmacies in Beijing are selling Chinese medicine tablets, more and more consumers accept and buy Chinese medicine tablets. Huge market share coupled with consumer recognition, to attract Ruikang Pharmaceuticals, Kangmei Pharmaceuticals, Tianmei Pharmaceuticals and other enterprises plus code layout of Chinese medicine tablets field. According to the analysis, there will be more enterprises in the future layout of Chinese medicine tablets business, but the domestic Chinese medicine drink tablets market still exists the lack of unified classification standards and other issues, under the attention of national policies, the domestic Chinese medicine drink tablets market will achieve standardized, centralized development.rapid development
Chinese medicine tablets ushered in a period of rapid development. According to the latest data, China's Chinese medicine tablet market is expected to grow by 19% and 17% respectively in 2017 and 2018, with the market size exceeding 270 billion yuan in 2018. According to the completion of the main economic indicators of the pharmaceutical industry in the first half of 2017 published on the official website of the Ministry of Industry and Information Technology, the Chinese medicine beverage tablet processing industry has developed rapidly in various sub-sectors of the pharmaceutical industry, with operating income and profits ranking first and second with growth of 21.33 percent and 22.78 percent, respectively.
Beijing Business Daily reporter in the recent visit found that bags, bulk, bottles and other different packaging of Chinese medicine tablets have become a necessary commodity for retail pharmacies. "Now many customers think that often take medicine is not good for the body, Chinese medicine tablets belong to Chinese medicine products, buy back do not need to be treated separately, when tea can play a certain effect, more and more consumers will buy Chinese medicine tablets." Salesmen at several retail pharmacies in Beijing said.
rapid development of the market coupled with the gradual recognition of domestic consumers, Kangmei Pharmaceuticals, Tianmei Pharmaceuticals, Ruikang Pharmaceuticals and other enterprises plus code layout of The field of Chinese medicine tablets. Recently, Kangmei Pharmaceutical Co., Ltd. plans to build 8 billion yuan, including Chinese herbal medicine trading center, Chinese herbal medicine storage and logistics center, Taoyuan medicinal standards assessment and research and development center and other projects of Kunming Health City. In January this year, Ruikang Pharmaceutical subscription is mainly engaged in the production and sale of Chinese medicine tablets Jingquan Pharmaceutical 20.82 million shares of stock layout plus code Chinese medicine tablets business. In June this year, Tianding Pharmaceuticals announced that it intends to purchase a 100% stake in Dechang Pharmaceuticals, which is mainly the production and sale of Chinese medicine tablets, for 360 million yuan.lack of
, origin, natural conditions and other factors lead to the same variety of Chinese medicine tablets more grade, lack of uniform classification standards. Analysts said that due to factors such as origin and natural conditions, the quality of the same kind of Chinese herbal medicines is very different, the price may be several times or even more than ten times the difference. The large difference in the quality of Chinese herbal medicine leads to a variety of levels of Chinese medicine tablets of the same variety, coupled with different preparation processes, further increasing the level of Chinese medicine tablets after processing.
Xie Xiaoliang, director of the Center for Medicinal Plant Research of Hebei Academy of Agricultural Sciences and chief expert of the Chinese medicine science and technology industry system, said in an interview with the Beijing Business Daily that at present, the overall non-conformity rate of Chinese herbal medicine is about 30%, and some traditional production areas have higher non-conformity rate, mainly because the content does not meet the standards of the Pharmacopoeia, impurities, ash, foreign pollutants and other excess standards. "The establishment of a traceability system for the quality of Chinese herbal medicines and the improvement and stabilization of the quality of herbal medicines are the key to the healthy development of the Chinese herbal medicine industry."
, there are problems such as production specialization and low scale of Chinese medicine tablets, which restrict the development of the beverage tablet industry. Industry insiders said that in the early days, the production of Chinese medicine tablets do not need to obtain GMP certificate, many "small workshops" production is not standardized. From January 1, 2008, all Chinese medicine tablet manufacturers are required to produce in accordance with GMP conditions. Although GMP transformation to some extent to rectify the production environment of drinking tablets, but because of drinking tablets production equipment does not match and other issues, most enterprises are difficult to complete the true sense of standardized production lines.Standardized Development
Guangzhou Guangzhou Guangzhou Hang Seng Securities Research Institute analysis shows that in 2015 there were 1006 Chinese medicine enterprises, low industry concentration, sales of less than 100 million enterprises accounted for 70% of the market. Under the great attention of national policy, China's Chinese medicine tablet industry is expected to move towards standardization, centralization, integration, small packaging and other trends. Kangmei Pharmaceuticals said in its semi-annual report this year that industry concentration is expected to increase as regulation of the Chinese medicine tablet industry becomes more stringent in recent years, and some smaller or non-compliant industry companies will be phased out.
, the State Pharmacopeia Commission held a media conference to introduce the key content and direction of the upcoming 2020 edition of the Chinese Pharmacopoeia. At the meeting, Zhang Wei, secretary-general of the National Pharmacopeia Commission, said that the 2020 edition of the Pharmacopeia will comprehensively formulate limits on heavy metals and harmful elements and pesticide residues of Chinese herbal medicine and Chinese medicine tablets, with emphasis on strengthening the research and formulation of quality standards for Chinese medicine tablets, and establishing and improving quality standards for Chinese medicine tablets.
analyst, who did not want to be named, said there was huge room in the Chinese medicine tablet market and more companies would lay out the field in the future. In addition, as the pace of life of domestic consumers continue to accelerate, consumer demand for the speed and portability of Chinese medicine tablets is also increasing year by year, the future of Chinese medicine tablets will be more and more variety to meet consumer demand. (Beijing Business Daily)